The cardiac sodium channel: gating function and molecular pharmacology
about
sameAs
Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytesNa⁺ transport in the normal and failing heart - remember the balanceChannelopathies from mutations in the cardiac sodium channel protein complexHuman iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correctionParameterization for In-Silico Modeling of Ion Channel Interactions with DrugsExpression pattern of neuronal and skeletal muscle voltage-gated Na+ channels in the developing mouse heartDistinct functional defect of three novel Brugada syndrome related cardiac sodium channel mutationsFever-triggered ventricular arrhythmias in Brugada syndrome and type 2 long-QT syndrome.Cardiac sodium channelopathies.Brugada syndrome: from cell to bedsideDimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome.A heterozygous deletion mutation in the cardiac sodium channel gene SCN5A with loss- and gain-of-function characteristics manifests as isolated conduction disease, without signs of Brugada or long QT syndrome.Inhibition of cardiac sodium currents by toluene exposureMolecular genetics of arrhythmias and cardiovascular conditions associated with arrhythmias.Brugada syndrome: clinical, genetic, molecular, cellular and ionic aspects.Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation.Brugada and long QT-3 syndromes: two phenotypes of the sodium channel disease.Characterization of maturation of neuronal voltage-gated sodium channels SCN1A and SCN8A in rat myocardium.Activation of protein kinase C alters the intracellular distribution and mobility of cardiac Na+ channels.Therapy for the Brugada syndrome.The role of the persistent Na(+) current during cardiac ischemia and hypoxia.The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.Cellular mechanism and arrhythmogenic potential of T-wave alternans in the Brugada syndromeAssessment of the Risk Factors and Outcomes for Postoperative Atrial Fibrillation Patients Undergoing Isolated Coronary Artery Bypass Grafting.Electrical heart disease: Genetic and molecular basis of cardiac arrhythmias in normal structural hearts.Cardiac sodium channel mutations: why so many phenotypes?Cardiac sodium channels and inherited electrophysiologic disorders: a pharmacogenetic overview.Pathophysiology of the cardiac late Na current and its potential as a drug target.Localization of sodium channel subtypes in mouse ventricular myocytes using quantitative immunocytochemistry.Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.Dysfunction in ankyrin-based cellular pathways and human cardiac arrhythmia.Redox control of cardiac excitability.Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspects.Pharmacogenetics of drug-induced arrhythmias.Reduced Penetrance and Variable Expression of SCN5A Mutations and the Importance of Co-inherited Genetic Variants: Case Report and Review of the Literature.SCN5A-linked disease syndromes: complex monogenic disorders of cardiac rhythm.The intracellular domain of the beta 2 subunit modulates the gating of cardiac Na v 1.5 channels.Action potential changes associated with a slowed inactivation of cardiac voltage-gated sodium channels by KB130015.In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics.Modulation of Nav1.5 channel function by an alternatively spliced sequence in the DII/DIII linker region.
P2860
Q24319636-7BA31067-68FB-41B2-94E5-568D361F86F2Q24338863-9163BEFC-F199-4839-B3BA-62447A4DF7D2Q26824051-BB219A57-547E-4E90-824D-5468F8D8E252Q27322725-3F7FAFD7-BFCB-401B-9268-2BED18D4782AQ28550678-E6CC95DF-6EBD-44D4-835C-58BF7E48BE43Q28588673-0C682B29-D1F3-49E5-BEA2-2CA57CBE8AE8Q33157184-FF568C89-FC6B-4B11-BC74-8E4CCCE80E40Q33764745-043861E9-AB0F-4989-AA66-4F9528BB5D32Q33906972-6696E1C2-D079-4E9E-8AC1-743E9878F745Q34667046-A1ADF0A4-D372-4784-89B2-24B1A1F2015EQ34667644-F2F8DC51-0A3E-4075-B75C-FB67625B9C4DQ34808264-6E164CB0-3099-4D21-9E7D-7631A1E230E3Q35045778-AF03C5EF-88DC-4384-803B-810172A08A4BQ35586125-FB8282EE-B4F8-40A3-9E04-ECF6525E2A27Q35696399-F41E18F9-ECC5-4CC2-8547-2198559B7513Q35698299-45E85F64-AD8E-48F3-B5F5-E10E167BF4A1Q35831609-F0ADB3F7-9DB9-4B2E-BDA0-2DD8DAC85BEBQ35933311-E9D0EFAC-7869-44D8-867B-E6E7FDCB4EFDQ35964944-92807C35-F992-4F8E-9670-96753F66897AQ36446444-D6865FE0-2D53-4497-84B4-8924D4EF0A4AQ36474191-1F6133AA-1246-4E8A-8998-EB0AB9082DB1Q36597505-17DAE415-7FB4-4595-AD8C-81131268E8CBQ36631579-75C72DAF-D9FF-4325-9E3B-DF44A4FBF146Q36721211-DBFAFB31-E26C-4807-986F-29C1DD944FF2Q36898735-F6D07713-F1C5-415D-917E-492AFC813EE2Q36932045-D1E6FE21-66A0-4CA6-9A93-501F7843422DQ37098991-4D202301-742D-4D8A-9312-722A900F7896Q37276416-02968995-C270-47C5-AB3B-625FB0C11EF0Q37364551-DAE53E37-AD15-41E2-A55F-53869BF71BBEQ37495337-52577604-F372-4DAE-AA5E-86528A6BB952Q37608496-7EB6215D-3B36-4225-BA2F-37053037CA61Q38035054-8492F853-F814-4110-B05F-73DC0A8BCB7FQ38118751-55C5A172-AE55-4A18-82EF-E195B18E228EQ38177332-68E60433-6CC3-4F6A-9DAB-323054A1B97FQ38221847-46C8D9E5-1D85-47D7-9A8E-5BB3154F2EA7Q40457885-6E02F94B-7A45-4C44-B11C-AA7EAB962C7CQ42152097-B4B45A76-D9A6-423E-AB88-87296BC896B4Q42155526-CFD81663-9D48-48A8-BC5E-060456EADB13Q42160738-F9F022C6-F355-4517-BB04-4656252F19ABQ42680102-5478ED7D-E0B4-4CC0-9F63-9463CEBF6CFF
P2860
The cardiac sodium channel: gating function and molecular pharmacology
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The cardiac sodium channel: gating function and molecular pharmacology
@ast
The cardiac sodium channel: gating function and molecular pharmacology
@en
The cardiac sodium channel: gating function and molecular pharmacology
@nl
type
label
The cardiac sodium channel: gating function and molecular pharmacology
@ast
The cardiac sodium channel: gating function and molecular pharmacology
@en
The cardiac sodium channel: gating function and molecular pharmacology
@nl
prefLabel
The cardiac sodium channel: gating function and molecular pharmacology
@ast
The cardiac sodium channel: gating function and molecular pharmacology
@en
The cardiac sodium channel: gating function and molecular pharmacology
@nl
P356
P1476
The cardiac sodium channel: gating function and molecular pharmacology
@en
P2093
J R Balser
P304
P356
10.1006/JMCC.2000.1346
P407
P577
2001-04-01T00:00:00Z